PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

. Minder the Paperwork Reduction Act of 1995	5, no persor	ns are required to respond to a collection	n of information unless it displays a valid OMB con	trol number	
TIEBE		Application Number	10/618,183		
TRANSMITTAL	NSMITTAL	Filing Date	July 10, 2003		
		First Named Inventor	Stephen Epstein et al.		
1 Okto	FORM	Art Unit	1636		
(to be used for all correspondence after initial filing)		Examiner Name	R. Akhavan		
Total Number of Pages in This Submission	41	Attorney Docket Number	MEDIV2010-4		

the date shown below.

Typed or printed name

Karin E. Harden

Signature

ENCLOSURES (Check all that apply)					
Fee Trans	mittal Form		Drawing(s)		After Allowance Communication to TC
Fee	Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendme	nt/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After	r Final		Petition to Convert to a Provisional Application		Proprietary Information
Affid	avits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address		Status Letter
Extension of Time Request		Terminal Disclaimer		· · · •	
Express A	bandonment Request		Request for Refund		 International Search Report (1 pg.);
	n Disclosure Statement		CD, Number of CD(s) Landscape Table on CD		 References (4) Return Receipt Postcard
Document Document	Copy of Priority (s)	Ren	narks		
	to Missing Parts/ e Application				
	sponse to Missing Parts 37 CFR 1.52 or 1.53				
	SIGNATI	JRE O	F APPLICANT, ATTORNEY,	OR AG	ENT
Firm Name	DLA PIPER RUDNICK G	RAY (CARY US LLP		
Signature	Tisas Va	<u>ve</u>			
Printed name	Lisa A. Haile, J.D., Ph.D.				
Date	March 15, 2005			Reg. No.	38,347
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with					
			ile transmitted to the USPTO or deporessed to: Commissioner for Patents,		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

March 16, 2005





Attorney Docket No.: MEDIV2010-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Stephen Epstein et al.

Art Unit:

1636

Serial No.:

10/618,183

Examiner

R. Akhavan

Filed:

July 10, 2003

Confirmation Number

4304

Title:

INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM FOR

ANGIOGENESIS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, the references are listed on the attached Form PTO-1449 and a copy of the references are enclosed herewith. A copy of the International Search Report listing the references is also enclosed.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, March 16, 2005, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Karin E. Harden

(Name of Person Mailing Paper)

March 16, 2005

(Date

In re Application of: Stephen Epstein et al.

Application No.: 10/618,183

Filed: July 10, 2003

Page 2

Atty Docket No.: MEDIV2010-4

PATENT

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement, because it is being filed within three months of the date of entry of the national stage application as set forth in §1.491. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 07-1896.

Respectfully submitted,

Date: March 16, 2005

Lisa A. Haile, J.D., Ph.D. Registration No. 38,347 Telephone: (858) 677-1456 Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121-2133 USPTO CUSTOMER NO. 28213

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRACE Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of I1

Complete if Known

Application Number 10/618,183

Filing Date July 10, 2003

First Named Inventor Stephen Epstein et al.

Art Unit 1636

Examiner Name R. Akhavan

Attorney Docket Number MEDIV2010-4

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	AA	Chiu, "Adult stem cell therapy for heart failure", Expert Opinion Biol. Ther., March 2003, Vol. 3, pp. 215-215					
	AB	Dowell et al., "Myocyte and myogenic stem cell transplantation in the heart", Cardiovascular Research, Vol. 58, 2003, pp. 336-350					
	AC	Folkman, "Therapeutic Angiogenesis in Ischemic Limbs", Editorial, May 1998, Vol. 97, pp. 1108-1110					
, , , , , , , , , , , , , , , , , , , 	AD lwaguro et al., "Endothelial Progenitor Cell VAscular Endothelial Growth Factor Gene Transfer for Vascular Regeneration", Circulation, February 2002, Vol. 105, pp. 732-738						
Examiner		Date					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.